Banchette, Italy

Giacinto Rossi

This inventor holds 1 USPTO granted patent. Top assignee: Marxer S.p.a.. Active years: 1979.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1979

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Giacinto Rossi: Innovator in Cardiac Treatment

Introduction

Giacinto Rossi is a notable inventor based in Banchette, Italy. He has made significant contributions to the field of medical science, particularly in the treatment of cardiac conditions. His innovative work has led to the development of a unique therapeutic compound aimed at improving heart health.

Latest Patents

Rossi holds a patent for "Therapeutically active d-glucosamine salts." This invention focuses on the treatment of cardiac hypertrophy. The patent describes d-glucosamine salts of the 3',5'-adenosine monophosphoric cyclic acid (AMP-c) and its dibutyl ester. These salts exhibit reduced acute toxicity and enhanced activity on the mitochondria of hypertrophic hearts compared to the cyclic AMP acid alone or its dibutyl ester. The compounds are particularly useful for treating cardiac hypertrophy and altering energetic muscular metabolism.

Career Highlights

Giacinto Rossi is associated with Marxer S.p.a., where he applies his expertise in developing innovative medical solutions. His work has garnered attention for its potential impact on cardiac health and treatment methodologies.

Collaborations

Rossi collaborates with Alberto Reiner, contributing to advancements in their field. Their partnership exemplifies the importance of teamwork in driving innovation.

Conclusion

Giacinto Rossi's contributions to cardiac treatment through his patented inventions highlight the vital role of innovation in medicine. His work continues to pave the way for improved therapeutic options for patients suffering from cardiac conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…